Stage I Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia
This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 7 |
Est. completion date | October 2014 |
Est. primary completion date | April 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of 1 of the following - Histologically or cytologically confirmed squamous cell carcinoma of the skin - Unresectable or metastatic disease - Squamous cell histology represents = 50% of the biopsy specimen - May or may not be related to autologous or allogeneic organ transplantation - Chronic lymphocytic leukemia (CLL) - RAI stage 0-I - Stable disease - Patients with basalosquamous cell disease (basal cell with squamous differentiation) are eligible - Measurable disease, defined as at least 1 unidimensionally measurable lesion = 20 mm by conventional techniques or = 10 mm by spiral CT scan - Must be willing to undergo a pre-treatment tumor biopsy - Brain metastases are allowed provided the following are true: - Received definitive therapy consisting of external beam radiation therapy, gamma knife therapy, or surgical resection resulting in clinically stable disease - Lesions are under control for at least 4 weeks after completion of definitive therapy, as measured by repeat MRI or CT scans - No requirement for dexamethasone - ECOG performance status 0-1 OR Karnofsky 60-100% - Life expectancy > 6 months - WBC = 3,000/mm^3 - Absolute neutrophil count = 1,500/mm^3 - Platelets = 100,000/mm^3 - Total bilirubin = 1.5 times upper limit of normal(ULN) - AST/ALT = 2.5 times ULN - Potassium 3.5 - 5.1 mmol/L - Calcium > lower limit of normal - Creatinine = 1.5 times ULN OR creatinine clearance = 60 mL/min - No known HIV 1 or HIV 2 positivity - No known hepatitis C or hepatitis B positivity - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of allergic reactions attributed to compounds of similar chemical or biological composition to dasatinib - No QTc prolongation, defined as a QTc interval of = 480 msecs or other significant ECG abnormality - No condition that impairs the ability to swallow and retain dasatinib tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, prior surgical procedure affecting absorption, or active peptic ulcer disease) - No clinically significant cardiovascular disease including the following: - Myocardial infarction within 6 months - Uncontrolled angina within 3 months - Diagnosed or suspected congenital long QT syndrome - Any history of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsades de Pointe) - Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker) - Heart rate consistently < 50 beats/minute on pre-entry ECG - Uncontrolled hypertension - Ejection fraction < 45% by transthoracic echo - No uncontrolled intercurrent illness including, but not limited to, the following: - Ongoing or active infection requiring intravenous antibiotics - History of significant bleeding disorder, including congenital (von Willebrand's disease) or acquired (anti-factor VIII antibodies) disorders - Psychiatric illness or social situations that would limit compliance with study requirements - No prior malignancy except for adequately treated basal cell cancer, carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years - No gastro-esophageal reflux disease dependent on proton pump inhibitors, H2 blockers, or antacids - Recovered from prior therapy - No more than 1 prior therapy with a monoclonal antibody - No more than 1 prior chemotherapy regimen - No prior tyrosine kinase inhibitor therapy - Prior erlotinib hydrochloride allowed - More than 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered - At least 4 weeks since prior radiotherapy - Measurable disease must be outside the radiotherapy port - At least 2 weeks since prior topical therapy - At least 4 weeks since prior surgery requiring general anesthesia and intubation - At least 120 days (4 months) since prior amiodarone - At least 7 days since prior and no concurrent anti-thrombotic and/or platelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin [full dose and 81 mg dose] and/or ibuprofen) - At least 7 days since prior and no concurrent agents with pro-arrhythmic potential - More than 7 days or 5 half lives, whichever is greater, since prior and no concurrent agents or substances that induce or inhibit CYP3A4 - No concurrent bisphosphonate therapy for the first 8 weeks of dasatinib treatment - No other concurrent investigational agents - No concurrent combination antiretroviral therapy for HIV-positive patients |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Ohio State University Medical Center | Columbus | Ohio |
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (Complete Response and Partial Response) | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | Every 2 courses during treatment, assessed up to 12 weeks after completion of treatment | No |
Secondary | Progression-free Survival | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | Time from start of treatment to time of progression, assessed up to 12 weeks | No |
Secondary | Presence of Total EphA2 and Both Total and Active Src and FAK by Immunohistochemistry (IHC) | Performed per standard protocols by the Pathology Department. | At baseline | No |
Secondary | COX-2 Presence by IHC | Performed per standard protocols by the Pathology Department. Samples will be obtained pre-therapy. Determination of the COX-2 tumor status on this trial will develop the beginnings of a data base upon which future therapy may be designed. | At baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Terminated |
NCT00377104 -
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01441882 -
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT00288067 -
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00098670 -
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT02100423 -
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Terminated |
NCT00303966 -
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT01351896 -
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT01024010 -
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT01789255 -
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT01361711 -
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00918723 -
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00003620 -
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT02309515 -
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
|
Phase 2 | |
Active, not recruiting |
NCT02213913 -
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
|
Phase 1/Phase 2 | |
Completed |
NCT01269385 -
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT01649791 -
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
|
N/A |